Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang EIERMANN, Владимир Федорович Семиглазов et al. · The Lancet · 2010
Cited by 1,255 works. doi:10.1016/s0140-6736(09)61964-4
Authors
- Luca Gianni
- Wolfgang EIERMANN
- Владимир Федорович Семиглазов
- Alexey Manikhas
- Ana M. Lluch
- Sergey A. Tjulandin
- Milvia Zambetti
- Mikhail Byakhow
- Mikhail Lichinitser
- Miguel Ángel Climent
- Eva Ciruelos
- Belen Ojeda
- Mauro Mansutti
- Алла Александровна Божок
- Roberta Baronio
- Andrea Feyereislova
- Claire M. Barton
- Pinuccia Valagussa
- José Baselga
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
- Modelling for Survival Data in Medical Research
- Modelling Survival Data in Medical Research.
- Minimization: A new method of assigning patients to treatment and control groups
- USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial